Sonidegib is used primarily used to treat adults with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or for those who are not candidates for surgery or radiation therapy.
It is marketed under the brand name Odomzo.
Sonidegib is a Hedgehog (Hh) pathway inhibitor.
The Hedgehog pathway plays a crucial role in cell growth and differentiation.
With basal cell carcinoma, this pathway can become abnormally activated, leading to uncontrolled cell growth.
Sonidegib blocks a key component of the Hh pathway (the SMO protein), thereby inhibiting cancer cell growth and survival.
It is taken orally, usually as a capsule.
Side Effects: Common side effects may include: – Muscle spasms – Hair loss – Fatigue – Nausea – Diarrhea – Decreased appetite – Changes in taste
It can cause severe birth defects, so it’s crucial for both male and female patients to use effective contraception.
Regular blood tests are needed to monitor liver function and creatine kinase levels.